Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.55 |
| ▸ | GABRP | O00591 | 1/20 | 0.55 |
| ▸ | GABRD | O14764 | 1/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320323 | 1.00 | CHRM1 (1.00) | CHRM1ALOX12SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7322840 | 0.87 | CHRM1 (0.77) | CHRM1ALOX12SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7324382 | 0.87 | CHRM1 (0.77) | CHRM1ALOX12SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7330628 | 0.87 | ALOX12 (1.00) | CHRM1ALOX12SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11733109 | 0.85 | CHRM1 (0.73) | CHRM1ALOX12SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7950385 | 0.85 | CHRM1 (1.00) | CHRM1ALOX12SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL7324283 | 0.85 | CHRM1 (0.73) | CHRM1ALOX12SMN1; SMN2LMNAALDH1A1 | |
| N-Desalkyl-2-Oxoquazepam SCHEMBL30730010 | 0.85 | LMNA (1.00) | CHRM1ALOX12SMN1; SMN2LMNACHRM5 | |
| N-Desalkyl-2-Oxoquazepam SCHEMBL30529978 | 0.85 | LMNA (1.00) | CHRM1ALOX12SMN1; SMN2LMNACHRM5 | |
| N-Desalkyl-2-Oxoquazepam SCHEMBL5177297 | 0.85 | LMNA (1.00) | CHRM1ALOX12SMN1; SMN2LMNACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112028843-A | Preparation method of 7-chloro-5- (2-fluorophenyl) -3H-1, 4-benzodiazepine-2-methylamine | 北京益民药业有限公司 | 2020-12-04 | — | — | CN | claimed |
| US-20260042763-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2026-02-12 | — | — | US | disclosed |
| CN-118043326-A | Benzodiazepine derivatives as GABAA γ1 PAM | 豪夫迈·罗氏有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4299126-A2 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3160969-B1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11136322-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210163490-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2021-06-03 | — | — | US | disclosed |
| CN-112028843-A | Preparation method of 7-chloro-5- (2-fluorophenyl) -3H-1, 4-benzodiazepine-2-methylamine | 北京益民药业有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-112028843-A | Preparation method of 7-chloro-5- (2-fluorophenyl) -3H-1, 4-benzodiazepine-2-methylamine | 北京益民药业有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-10844070-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2015200766-A2 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-0801651-B1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | disclosed |
| US-6174881-B1 | USED AS ANXIOLYTIC AND/OR ANTICONVULSANT AND/OR MUSCLE RELAXANT AGENTS; SEDATIVES OR HYPNOSIS; WATER-SOLUBLE AMINE SALTS; FAST-ACTING | HOFFMAN-LA ROCHE INC. | 2001-01-16 | — | — | US | disclosed |
| EP-0801651-A1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-22 | — | — | EP | disclosed |
| WO-1996020941-A1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-07-11 | — | — | WO | disclosed |
| EP-0041242-B1 | CARBAMOYLOXYAMINO-1,4-BENZODIAZEPINES, THEIR PREPARATION AND MEDICINES CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-07-11 | — | — | EP | disclosed |
| US-4395409-A | ANXIOLYTIC AGENT | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-26 | — | — | US | disclosed |
| US-3992408-A | CHEMICAL INTERMEDIATES | THE UPJOHN COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3987052-A | SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3933794-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844070-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | SLC6A13, SI, SLC6A11 | CHRM1 746/4885ALOX12 3638/4885SMN1; SMN2 1974/4885 |
| US-11136322-B2 | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | SLC6A13, SI, SLC6A11 | CHRM1 746/4885ALOX12 3638/4885SMN1; SMN2 1974/4885 |
| US-20260042763-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | GABRB2, GABRB3, GABRB1 | CHRM1 283/4885ALOX12 1699/4885SMN1; SMN2 954/4885 |
| US-20210163490-A1 | PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM | SLC6A13, SI, SLC6A11 | CHRM1 746/4885ALOX12 3638/4885SMN1; SMN2 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.